Alnylam Pharmaceuticals
Alnylam Pharmaceuticals19About
Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company that develops innovative therapies based on RNA interference (RNAi). By silencing disease-causing genes at the genetic level, the company provides transformative treatments for patients with rare and common genetic, metabolic, and cardiovascular diseases.
Comments
No comments yet. Be the first to share your take.
Frequently asked
What does Alnylam Pharmaceuticals do?
Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company that develops innovative therapies based on RNA interference (RNAi). By silencing disease-causing genes at the genetic level, the company provides transformative treatments for patients with rare and common genetic, metabolic, and cardiovascular diseases.
Where is Alnylam Pharmaceuticals headquartered?
Alnylam Pharmaceuticals is headquartered in Cambridge, Massachusetts, United States.
When was Alnylam Pharmaceuticals founded?
Alnylam Pharmaceuticals was founded in 2002.
What industry does Alnylam Pharmaceuticals operate in?
Alnylam Pharmaceuticals operates in Biotechnology, Pharmaceuticals, Healthcare.
What is Alnylam Pharmaceuticals's valuation?
StartupHub estimates Alnylam Pharmaceuticals's effective valuation at $26.0B (range $18.2B to $65.3B, 58% confidence), based on comparable companies in the sector.